SCHEMBL559735

SCHEMBL559735

CC(=O)Nc1cnc(N)c(-c2nc3ccccc3[nH]2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 14/20 0.60
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 2/20 0.53
TP53 P04637 1/20 0.53
POLB P06746 1/20 0.53
AURKA O14965 1/20 0.53
CDK1 P06493 1/20 0.53
CCNB1 P14635 1/20 0.53
CDK2 P24941 1/20 0.53
AURKB Q96GD4 1/20 0.53
PRKDC P78527 1/20 0.53
ATM Q13315 1/20 0.53
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
LMNA P02545 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CHEK2 O96017 1/20 0.47
SYK P43405 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560151 0.78 KMT2A (0.56) ATRKDM4EALDH1A1TP53POLB
SCHEMBL2509332 0.76 ATR (1.00) ATRPRKDCATM
SCHEMBL560241 0.75 ATR (0.68) ATRKDM4EALDH1A1TP53POLB
SCHEMBL10135119 0.74 ATR (0.64) ATRKDM4EALDH1A1CDK1CDK2
SCHEMBL13354021 0.74 ATR (0.67) ATRKDM4EALDH1A1TP53POLB
SCHEMBL559844 0.73 ATR (0.56) ATRPRKDCATM
SCHEMBL615478 0.73 CKS1B (0.52) ATRPRKDCATM
SCHEMBL615477 0.73 CKS1B (0.52) ATRPRKDCATM
SCHEMBL13138778 0.72 ATR (0.78) ATRKDM4EALDH1A1PRKDCATM
SCHEMBL13138782 0.72 ATR (0.77) ATRPRKDCATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885KDM4E 2074/4885ALDH1A1 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.